Larimar Therapeutics, INC 8-K filings

Larimar Therapeutics held its 2024 Annual Meeting of Stockholders, where key proposals including the election of directors and ratification of the company's accounting firm were approved.

Larimar Therapeutics' nomlabofusp has been chosen to participate in the FDA's Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program, aimed at accelerating the development of novel therapies for rare diseases.

The FDA has removed the partial clinical hold on Larimar Therapeutics' nomlabofusp program, allowing the company to proceed with dose escalation in its ongoing open-label extension study.

Larimar Therapeutics announced positive results from its Phase 2 study of nomlabofusp, along with a strengthened financial position, and is advancing towards a BLA submission.

Larimar Therapeutics reported positive results from its Phase 2 trial of nomlabofusp, showing dose-dependent increases in frataxin levels, and secured $161.6 million in funding, extending its operating runway into 2026.

Larimar Therapeutics has dosed the first patient in its open-label extension study of nomlabofusp for Friedreich's ataxia, aiming for accelerated approval based on frataxin levels.

Larimar Therapeutics successfully completed a public offering of common stock, raising approximately $161.8 million in net proceeds.

Larimar Therapeutics has terminated its $50 million sales agreement with Guggenheim Securities, under which no shares were ever sold.

Larimar Therapeutics reported positive top-line data from its Phase 2 dose exploration study of nomlabofusp, showing dose-dependent increases in frataxin levels in patients with Friedreich's ataxia.